Shopping Cart
- Remove All
- Your shopping cart is currently empty
JNU-0921 is an effective orally-active inhibitor of CD137. It enhances the mRNA expression of IFN-γ and GZMB and induces luciferase activity with an EC50 of 64.07 nM. JNU-0921 also boosts both the efficacy and memory function of cytotoxic CD8+ T cells (CTL), alleviating their exhaustion. Moreover, it promotes the polarization of helper T cells towards a Type 1 helper profile, thereby augmenting their activity to enhance CTL function. Additionally, JNU-0921 possesses anticancer properties.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | JNU-0921 is an effective orally-active inhibitor of CD137. It enhances the mRNA expression of IFN-γ and GZMB and induces luciferase activity with an EC50 of 64.07 nM. JNU-0921 also boosts both the efficacy and memory function of cytotoxic CD8+ T cells (CTL), alleviating their exhaustion. Moreover, it promotes the polarization of helper T cells towards a Type 1 helper profile, thereby augmenting their activity to enhance CTL function. Additionally, JNU-0921 possesses anticancer properties. |
Molecular Weight | 316.31 |
Formula | C19H12N2O3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.